CellGenix registers FDA Drug Master Files for ex-vivo CellGro® TNF-a and GM-CSF
Advertisement
CellGenix has registered two new drug master files for TNF-a and GM-CSF. After filing a DMF for IL-4, this contributes further to the strategy of producing highest quality cytokines for the use in clinical ex-vivo cell culturing in connection with cell processing kits. As proposed in the new USP chapter 1043, which became effective on April 1, a DMF cross reference is recommended for all ancillary materials used in clinical cell therapy.
Together with further quality and safety features, like animal-derived-free raw materials or batch-specific certificates-of-analysis, CellGenix´ ex-vivo grade cytokines fulfil all major recommendations given in USP 1043.
The cytokines are produced under cGMP-conditions, expressed in E-coli and no animal derived raw materials are used in the production or purification process. TNF-a and GM-CSF are intended for ex-vivo use only. Batch-specific Certificates of Analysis are issued and sent with each delivery.
CellGenix has filed these two DMFs which enable an investigator, upon written approval of CellGenix, to cross-reference either DMF in their own sponsored IND-application using ex-vivo processed cells in clinical research.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.